PFBT
ITCI

Parkside Financial Bank & Trust’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Parkside Financial Bank & Trust’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1
Closed -$132 – 3041
2025
Q1 		$132 Buy
+1
New +$125 ﹤0.01% 2706

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Parkside Financial Bank & Trust's ITCI Position: Q2 2025 in Review

Parkside Financial Bank & Trust sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 1 share — an estimated $132 sold.

Parkside Financial Bank & Trust first reported a position in ITCI in Q1 2025 and held it in 1 quarter. The position peaked at $132 in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Parkside Financial Bank & Trust reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Parkside Financial Bank & Trust sold 1 Intra-Cellular Therapies Inc. share in Q2 2025, an estimated $132.
  • Parkside Financial Bank & Trust first reported a position in Intra-Cellular Therapies Inc. in Q1 2025 and held it in 1 quarter.
  • Parkside Financial Bank & Trust's Intra-Cellular Therapies Inc. position peaked at $132 in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2025, filed 7 Aug 2025.